SAGE Therapeutics (SAGE) Given a $170.00 Price Target by Oppenheimer Analysts

SAGE Therapeutics (NASDAQ:SAGE) has been given a $170.00 target price by equities research analysts at Oppenheimer in a research note issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target indicates a potential upside of 45.05% from the stock’s current price.

Several other equities analysts have also recently weighed in on SAGE. Canaccord Genuity set a $220.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 8th. Stifel Nicolaus raised their price objective on SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. BidaskClub upgraded SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 18th. Piper Jaffray Companies assumed coverage on SAGE Therapeutics in a research note on Monday, August 6th. They set an “overweight” rating and a $206.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $204.50.

Shares of SAGE opened at $117.20 on Monday. SAGE Therapeutics has a 12-month low of $59.65 and a 12-month high of $195.97. The firm has a market capitalization of $5.59 billion, a P/E ratio of -16.53 and a beta of 2.92.



SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million for the quarter. On average, analysts predict that SAGE Therapeutics will post -7.32 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in shares of SAGE Therapeutics by 1.6% during the 2nd quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock valued at $1,092,169,000 after purchasing an additional 110,687 shares during the last quarter. OppenheimerFunds Inc. increased its position in shares of SAGE Therapeutics by 2.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock valued at $250,162,000 after purchasing an additional 34,389 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock valued at $244,898,000 after purchasing an additional 110,134 shares during the last quarter. BB Biotech AG increased its position in shares of SAGE Therapeutics by 6.9% during the 2nd quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock valued at $167,702,000 after purchasing an additional 68,934 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of SAGE Therapeutics by 1.8% during the 2nd quarter. Jennison Associates LLC now owns 805,361 shares of the biopharmaceutical company’s stock valued at $126,063,000 after purchasing an additional 14,338 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: Understanding Average Daily Trade Volume

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply